Johnson & Johnson (JNJ) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a research note issued to investors on Wednesday. The firm currently has $145.00 price target on the stock.

According to Zacks, “J&J’s sales growth accelerated in the second half of 2017 backed by higher sales in the Pharmaceutical segment and improving performance in Medical Devices. Though quite a few key products in J&J’s portfolio like Remicade and Concerta are facing generic competition, we believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions – mainly Actelion – can support top-line growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. J&J’s shares have outperformed the industry in the past six months. However, headwinds like generics, pricing pressure and soft global market conditions remain. Estimates have risen slightly ahead of Q1 results. J&J has a positive record of earnings surprises in the recent quarters.”

Several other brokerages have also recently issued reports on JNJ. Wells Fargo restated an outperform rating and issued a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Vetr upgraded Johnson & Johnson from a hold rating to a buy rating and set a $150.89 target price for the company in a report on Thursday, January 11th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the company a hold rating in a report on Monday, January 22nd. Royal Bank of Canada reiterated a buy rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Finally, BTIG Research reiterated a sell rating and set a $110.00 price target on shares of Johnson & Johnson in a report on Wednesday, January 24th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of Hold and an average target price of $144.03.



Shares of NYSE:JNJ opened at $130.62 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. The firm has a market capitalization of $349,930.91, a price-to-earnings ratio of 17.89, a P/E/G ratio of 2.07 and a beta of 0.74. Johnson & Johnson has a 52-week low of $120.95 and a 52-week high of $148.32.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. The company had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.58 EPS. equities analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

In related news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.22% of the company’s stock.

A number of institutional investors have recently made changes to their positions in JNJ. BlackRock Inc. raised its position in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. Janus Henderson Group PLC raised its position in Johnson & Johnson by 717.9% in the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after purchasing an additional 3,289,763 shares in the last quarter. Vanguard Group Inc. raised its position in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. Parametric Portfolio Associates LLC raised its position in Johnson & Johnson by 47.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after purchasing an additional 2,581,562 shares in the last quarter. Finally, Stifel Financial Corp raised its position in Johnson & Johnson by 6,715.9% in the 3rd quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock valued at $334,777,000 after purchasing an additional 2,534,918 shares in the last quarter. Institutional investors own 67.24% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://dakotafinancialnews.com/2018/04/14/johnson-johnson-jnj-upgraded-at-zacks-investment-research-2.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply